Tyra shares drop more than 20% after Phase 2 bladder cancer results
Tyra Biosciences (TYRA) fell more than 20% in premarket trading after initial SURF302 Phase 2 results for its lead candidate dabogratinib in FGFR3-altered low bladder cancer patients.